RCN3 functions as a tumor promoter in colorectal cancer by modulating the GRP78-PI3K-AKT signaling pathway.

It is suggested that RCN3 not only contributes to CRC progression but also holds promise as a potential therapeutic target and biomarker for improving patient outcomes in CRC management.